VIP and PACAP inhibit activation induced apoptosis in T lymphocytes
- PMID: 11193880
- DOI: 10.1111/j.1749-6632.2000.tb06951.x
VIP and PACAP inhibit activation induced apoptosis in T lymphocytes
Abstract
Apoptosis in T and B lymphocytes is a major element controlling the immune response. Activation induced cell death (AICD) in T cells is a main mechanism for maintaining peripheral tolerance and for limiting an ongoing immune response. AICD is initiated by antigen reengagement of the T cell receptor (TCR), and mediated through Fas/Fas ligand (FasL) interactions. VIP and PACAP are two multifunctional neuropeptides present in the lymphoid microenvironment that act primarily as anti-inflammatory agents. In this study we report on the role of VIP and PACAP on T cell AICD, and on the mechanisms involved. VIP and PACAP inhibit AICD in vivo and in vitro, in peripheral T cells and T cell hybridomas. The effect is dose dependent and is mediated through the specific receptors VPAC1 and VPAC2. The inhibition of AICD is achieved through reduction in FasL expression at protein and mRNA level. By affecting FasL expression, VIP and PACAP may play a physiological role in both the generation of memory T cells and the inhibition of FasL-mediated T cell cytotoxicity.
Similar articles
-
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.J Immunol. 2000 Feb 1;164(3):1200-10. doi: 10.4049/jimmunol.164.3.1200. J Immunol. 2000. PMID: 10640731
-
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.J Immunol. 2001 Jan 15;166(2):1028-40. doi: 10.4049/jimmunol.166.2.1028. J Immunol. 2001. PMID: 11145682
-
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.J Immunol. 2000 Jul 1;165(1):114-23. doi: 10.4049/jimmunol.165.1.114. J Immunol. 2000. PMID: 10861043
-
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity.Crit Rev Oral Biol Med. 2002;13(3):229-37. doi: 10.1177/154411130201300303. Crit Rev Oral Biol Med. 2002. PMID: 12090463 Review.
-
The neuropeptides VIP/PACAP and T cells: inhibitors or activators?Curr Pharm Des. 2003;9(12):997-1004. doi: 10.2174/1381612033455116. Curr Pharm Des. 2003. PMID: 12678866 Review.
Cited by
-
Modulation of human neutrophil apoptosis by gut hormones.Int J Health Sci (Qassim). 2010 Jan;4(1):53-8. Int J Health Sci (Qassim). 2010. PMID: 21475526 Free PMC article.
-
Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture.J Mol Neurosci. 2010 Nov;42(3):419-27. doi: 10.1007/s12031-010-9349-6. Epub 2010 Apr 20. J Mol Neurosci. 2010. PMID: 20405239
-
Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion.J Mol Neurosci. 2010 Nov;42(3):411-8. doi: 10.1007/s12031-010-9342-0. Epub 2010 Mar 16. J Mol Neurosci. 2010. PMID: 20229361
-
Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia/reperfusion.J Mol Neurosci. 2008 Nov;36(1-3):89-96. doi: 10.1007/s12031-008-9064-8. Epub 2008 May 14. J Mol Neurosci. 2008. PMID: 18478450
-
Protective Effects of PACAP in Peripheral Organs.Front Endocrinol (Lausanne). 2020 Jul 14;11:377. doi: 10.3389/fendo.2020.00377. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32765418 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous